This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kufner, S. Search for Related Content PubMed Articles by Kufner, S.

Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis

Sebastian Kufner, MD^_*, Jörg Hausleiter, MD^_*, Gjin Ndrepepa, MD^_*, Stefanie Schulz, MD^_*, Olga Bruskina, MD^_*, Robert A. Byrne, MB^_*, Massimiliano Fusaro, MD, Adnan Kastrati, MD^_*, Albert Schömig, MD^_*,, Julinda Mehilli, MD^_*,_* for the OSIRIS Trial Investigators

^_* Deutsches Herzzentrum, Technische Universität, Munich, Germany
1. Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany

View larger version (10K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Primary Outcome of Interest Kaplan-Meier curves for survival free of myocardial infarction and target vessel revascularization for placebo, usual-dose, or high-dose sirolimus groups at 4 years.

View larger version (18K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Incidence of Target Vessel Revascularization for Placebo, Usual-Dose Sirolimus, or High-Dose Sirolimus Groups at 1- and 4-Year Follow-Up

View larger version (10K): [in this window] [in a new window] [Download PPT slide]   Figure 3 Cumulative Incidence of Newly Diagnosed Malignancies for Placebo, Usual-Dose Sirolimus, or High-Dose Sirolimus Groups at 4 Years

View larger version (16K): [in this window] [in a new window] [Download PPT slide]   Figure 4 Distribution of Different Entities of De Novo Malignancies for Placebo, Usual-Dose Sirolimus, or High-Dose Sirolimus Groups at 4 Years CNS = central nervous system; CUP = cancer of unknown primary origin; NHL = non-Hodgkin lymphoma.